News

Vedanta Biosciences publishes phase 1a/1b results for lead program VE303 in cell host & microbe and highlights planned presentations of phase 2 VE303 results

Vedanta Biosciences publishes phase 1a/1b results for lead program VE303 in cell host & microbe and highlights planned presentations of phase 2 VE303 results

BAKERSFIELD | Vedanta Biosciences, a leading clinical-stage company developing a potential new category of oral therapies based on defined bacterial consortia, today announced the publication in the journal Cell Host & Microbe of the results from a Phase 1a/1b study evaluating the safety, tolerability, and colonization dynamics of VE303 in healthy adults. VE303 is a potential first-in-class defined bacterial consortium candidate for the prevention of recurrent Clostridium difficile infection (CDI). The company will also share three research updates across its VE303 and VE202 (for inflammatory bowel disease) programs in podium presentations at Digestive Disease Week in May 2022.

Full Story